- Article
- Source: Campus Sanofi
- 23 Oct 2023
Praluent® (alirocumab) mechanism of action
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Picture12.jpg/jcr:content/Picture12.jpg)
![Praluent logo](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/unmet-needs/Image/praluent_registered_4c_left_triangle_notag.jpg2/jcr:content/praluent_registered_4c_left_triangle_notag.jpg)
Praluent® is a fully human monoclonal antibody1 that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) from binding to LDL-Rs, increasing the number of LDL-Rs available to remove LDL-C from the circulation.1,2
Without PCSK9 inhibition, PCSK9 decreases the number of available LDL-Rs on liver cells, resulting in higher LDL-C levels in the bloodstream.1
PCSK9 inhibition with Praluent® increases the number of available LDL-Rs, resulting in lower LDL-C levels in the bloodstream.1
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/desktop_moa_pcsk9_diagram--1-.jpg/jcr:content/desktop_moa_pcsk9_diagram%20(1).jpg)
Figure © Sanofi.
Watch the video below to learn more about the mechanism of action for Praluent®
Praluent®
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/unmet-needs/Image/Group-44.jpg/jcr:content/Group%2044.jpg)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/london-symposium-talk4/Image/MicrosoftTeams-image--2-.jpg/jcr:content/MicrosoftTeams-image%20(2).jpg)
References
LDL-C=low-density lipoprotein cholesterol; LDL-R=low-density lipoprotein receptor; PCSK9i=proprotein convertase subtilisin/kexin type 9 inhibitor.
- Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed October 2023.
- Poirier S and Mayer G. Drug Des Devel Ther 2013;7:1135–1148.
MAT-XU-2204608 (v3.0) Date of Preparation: October 2023